|
Glioma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Altered activities of long noncoding RNAs (lncRNAs) have been associated with cancer development, and lncRNA FOXD1-AS1 (FOXD1-AS1) is the antisense transcript of the gene encoding for FOXD1, known for its role as an oncogene in several tumor types including glioma.
|
31102349 |
2020 |
|
Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
FOXD1 was identified as the up-regulated gene in glioma based on microarray data of GSE65626.
|
30225541 |
2018 |
|
Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of FOXD1 is observed in glioma, lung cancer and breast cancer.
|
29864920 |
2018 |
|
Glioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We examined the expression and function of Forkhead box D1 (FOXD1) in glioma cell behavior and found that FOXD1 was upregulated and directly correlated with the glioma grade.
|
28075458 |
2017 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
|
30792394 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
|
30792394 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, both our data and TCGA data found that high expression of FOXD1 predicted poor prognosis of CRC patients.
|
29864920 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings indicate that FOXD1 promotes tumorgenesis and progression of CRC by activating ERK 1/2 signaling pathway and may represent a potential clinical target.
|
29887965 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In vivo assay further showed the inhibition of tumor growth after knockdown of FOXD1.
|
29936179 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.
|
30225541 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Our clinical data indicated that high FOXD1 level was associated with tumor size (≥5 cm) and TNM tumor stage (III + IV).
|
29864920 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In vitro assay showed that inhibitior of FOXD1 suppressed cell proliferation, migration and invasion in MG63 and U2OS cells, while overexpression of FOXD1 promoted OS cell proliferation and migration.
|
29936179 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We conclude that FOXD1 may influence invasion and migration via indirect regulation of MMP9 and RAC1B alternative splicing in melanoma cells.
|
30110134 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of FOXD1 attenuated CRC cell proliferation, migration and invasion.
|
29887965 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer.
|
29864920 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
FOXD1 predicts prognosis of colorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway.
|
29887965 |
2018 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Altered activities of long noncoding RNAs (lncRNAs) have been associated with cancer development, and lncRNA FOXD1-AS1 (FOXD1-AS1) is the antisense transcript of the gene encoding for FOXD1, known for its role as an oncogene in several tumor types including glioma.
|
31102349 |
2020 |
|
Primary malignant neoplasm
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Altered activities of long noncoding RNAs (lncRNAs) have been associated with cancer development, and lncRNA FOXD1-AS1 (FOXD1-AS1) is the antisense transcript of the gene encoding for FOXD1, known for its role as an oncogene in several tumor types including glioma.
|
31102349 |
2020 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Dysregulation of forkhead box D1 (FOXD1) is known to promote tumor progression; however, its molecular mechanism of action is unclear.
|
31795213 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Molecular, structural, and functional aspects of FOXD1 are presented in light of physiological and pathogenic conditions, including its role in human disease aetiology, such as cancer and recurrent pregnancy loss.
|
29959475 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The functional roles of FOXD1 in NSCLC were demonstrated cell viability CCK-8 assay, colony formation, cell invasion and migration assays, and cell apoptosis assay in vitro.
|
30562753 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, its expression pattern in colorectal cancer (CRC) and the molecular mechanism of FOXD1 on cancer progression remain unknown.
|
29887965 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that FOXD1 was aberrantly overexpressed in human CRC tissues, and FOXD1 levels were correlated with tumor size, differentiation, TNM stage and lymph node metastasis and poor prognosis.
|
29887965 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Molecular, structural, and functional aspects of FOXD1 are presented in light of physiological and pathogenic conditions, including its role in human disease aetiology, such as cancer and recurrent pregnancy loss.
|
29959475 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.
|
25550559 |
2015 |